International Laboratories, LLC Issues Voluntary Nationwide Recall Of One (1) Lot Of Pravastatin Sodium Tablets USP, 40 Mg Packaged In Bottles Of 30 Tablets Due To Mislabeling

Published: Aug 11, 2017

ST. PETERSBURG, Fla., Aug. 10, 2017 /PRNewswire/ -- International Laboratories, LLC is voluntarily recalling one (1) Lot of Pravastatin Sodium Tablets USP 40 mg packaged in bottles of 30 tablets, to the consumer level due to mislabeling.  The product is labeled as Pravastatin Sodium Tablets USP 40 mg but contained Bupropion Hydrochloride XL 300 mg tablets.

If a subject mistakenly takes bupropion, common side effects include: nausea, vomiting, dry mouth, headache, constipation, sweating, sore throat, diarrhea, dizziness, restlessness, blurry vision. These are typically minor and reversible issues. However, individuals with epilepsy are at higher risk of seizure on bupropion due to it lowering the seizure threshold. Also, people on MAOIs can have a risky drug interaction with bupropion (hypertensive crisis). Finally, allergic reactions are also possible and could be life threatening.

This lot of Pravastatin Sodium Tablets USP 40 mg was recalled when International Laboratories, LLC was informed by a pharmacist that one 30ct bottle of this product was mislabeled and contained Bupropion Hydrochloride XL 300 mg tablets. International Laboratories, LLC has reported that no complaints or reports of medical illnesses or harmful effects have been received to date.

Pravastatin Sodium Tablets USP 40 mg are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. It is used to treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.

Tablet image:
Pravastatin Sodium Tablet USP 40 mg

Tablet image: Pravastatin Sodium Tablet USP 40 mg

Bupropion hydrochloride extended-release tablets (XL) 300 mg are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD) in children, adolescents, young adults and adults.

The product was delivered to distribution centers in Arkansas, Georgia and Indiana and distributed to retail stores in Arkansas, Alabama, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota, Missouri, Mississippi, North Carolina, North Dakota, Nebraska, Ohio, Oklahoma, Puerto Rico, South Carolina, South Dakota, Tennessee, Texas, Virginia and Wisconsin.

International Laboratories, LLC is notifying its distributors and customer by letter and is arranging for return of all recalled products.  Consumers who have purchased this product should not open the package or use the contents. Instead, they should return the product to the location of purchase for a full refund, or call a Customer Complaint phone number at International Laboratories, LLC 727-322-7146 (Monday Friday 8 AM 5 PM EST).

Consumers with questions regarding this recall can contact International Laboratories, LLC by phone 727-322-7146 or e-mail address sutka.veselinovic@internationallabs.com on Monday - Friday 8AM 5PM EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact: 
Sutka Veselinovic
Phone: 727-322-7141
Email: sutka.veselinovic@internationallabs.com

 

International Labs, LLC.

View original content with multimedia:http://www.prnewswire.com/news-releases/international-laboratories-llc-issues-voluntary-nationwide-recall-of-one-1-lot-of-pravastatin-sodium-tablets-usp-40-mg-packaged-in-bottles-of-30-tablets-due-to-mislabeling-300502782.html

SOURCE International Laboratories, LLC

Back to news